Providers have the ability to order COVID-19 therapeutic products seven days a week through the Health Partner Ordering Portal (HPOP) in a process known as “threshold and replenishment.” In this process, the federal government replenishes the available supply, replacing products ordered by sites in the jurisdiction on a regular cadence (currently on a monthly basis). This ensures that the total amount of product available to jurisdictions is consistent, and this amount is known as a "threshold quantity."
Paxlovid (nirmatrelvir co-packaged with ritonavir) and Lagevrio (molnupiravir) threshold amounts are determined on a pro rata population basis and replenishment occurs monthly.
Requests for additional products can be made by central partners, including state and territorial health department officials, at any time if the current supply is not sufficient to meet demand. The federal government tracks the amount of COVID-19 therapeutic products ordered through the HPOP portal each week, monitoring product availability for each state or territory.
COVID-19 Therapeutics Summary: For All Open Distribution Channels1
December 17, 2021 –August 28, 2023
| Therapeutic |
Courses Delivered |
Courses Administered2 |
| Paxlovid3 |
15,440,583
|
9,918,591
|
Lagevrio
|
3,258,701
|
1,444,689
|
Total:
View Data by Jurisdiction
|
18,699,284 |
11,363,280 |
| Month/Year |
PDF by Date |
| July 2023 |
July 2, 2023 | July 30, 2023
|
| June 2023 |
June 4, 2023
|
| May 2023 |
May 7, 2023 |
May 14, 2023 |
May 21, 2023 |
May 28, 2023 |
| April 2023 |
April 2, 2023 |
April 9, 2023 |
April 16, 2023 |
April 23, 2023 |
April 30, 2023 |
| March 2023 |
March 5, 2023 |
March 12, 2023 |
March 19, 2023 |
March 26, 2023 |
| February 2023 |
February 5, 2023 |
February 12, 2023 |
February 19, 2023 |
February 26, 2023 |
| January 2023 |
January 1, 2023 |
January 8, 2023 |
January 15, 2023 |
January 22, 2023 |
January 29, 2023 |
| December 2022 |
December 4, 2022 |
December 11, 2022 |
December 18, 2022 |
December 26, 2022 |
| November 2022 |
November 6, 2022 |
November 13, 2022 |
November 20, 2022 |
November 27, 2022 |
| October 2022 |
October 2, 2022 |
October 9, 2022 |
October 16, 2022 |
October 23, 2022 |
October 30, 2022 |
| September 2022 |
September 4, 2022 |
September 11, 2022 |
September 18, 2022 |
September 25, 2022 |
The PDF data reflects data entry from providers; subsequent PDFs include any necessary data entry adjustments.
1 States, territories, and federal entities, including HRSA
2 Based on 91% of sites reporting this week
3 Includes Paxlovid and Renal Paxlovid
-
Data Source: Tiberius, Updated 08/28/2023 as of 1:00p EDT
-
Data through Sunday, 08/27/2023
COVID-19 Therapeutics Summary: Previously Distributed Products
2020 – 2023
Therapeutics
(currently not in use*) |
Date of
First Issue |
Date of
Last Distribution |
Courses
Delivered |
Courses
Administered |
| Evusheld (300mg doses) |
December 8, 2021 |
January 26, 2023 |
1,032,156 |
738,936 |
| Bebtelovimab |
February 11, 2022 |
November 30, 2022 |
739,889 |
624,633 |
| Sotrovimab |
May 26, 2021 |
April 5, 2022 |
706,692 |
302,209 |
| Bamlanivimab/Etesevimab |
February 9, 2021 |
January 24, 2022 |
642,125 |
610,753 |
| REGEN-COV |
November 21, 2020 |
January 24, 2022 |
2,878,138 |
2,078,587 |
| Bamlanivimab** |
November 9, 2020 |
March 2, 2021 |
664,691 |
N.A. |
*Products are not currently authorized for use in any U.S region due to high frequency of SARS-CoV-2 subvariants to which these therapeutics are unlikely to be effective.
**EUA was revoked for bamlanivimab when administered alone; courses administered data are not available at this time.
COVID-19 Therapeutics Threshold Determinations
May 1, 2023 - October 1, 2023
| Monthly Threshold Determinations* |
Paxlovid
(nirmatrelvir co-packaged with ritonavir;
standard and reduced dose) |
Lagevrio
(molnupiravir) |
Total |
|
August 28 - October 1, 2023 |
2,452,230 |
195,299 |
2,647,529 |
|
July 31 - August 27, 2023 |
2,452,230 |
195,299 |
2,647,529 |
|
July 1 - July 30, 2023 |
2,452,230 |
195,299 |
2,647,529 |
|
June 1 - June 30, 2023 |
2,450,200 |
194,911 |
2,645,111 |
|
May 1 - May 31, 2023 |
2,450,200 |
194,911 |
2,645,111 |
*Starting May 2023, COVID-19 therapeutic threshold determinations are made on a monthly cadence.
Prior COVID-19 Therapeutic Product Efforts
| Date Range |
Threshold/Distribution/Allocation by Jurisdiction |
April 25, 2022 - April 30, 2023
|
COVID-19 Therapeutics Threshold Determinations
|
| September 13, 2021 - April 24, 2022 |
COVID-19 Therapeutics Distribution |
| November 9, 2020 - March 2, 2021 |
Bamlanivimab Distribution |
| November 24, 2020 - February 2, 2021 |
REGEN-COV Distribution |
| July 6, 2020 - October 4, 2020 |
Allocation of Commercial Veklury (Remdesivir) (PDF) |
May 4, 2020 - June 29, 2020
|
Allocation of Donated Veklury (Remdesivir)
|
